These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31191199)

  • 1. Emicizumab in the Treatment of Acquired Haemophilia: A Case Report.
    Möhnle P; Pekrul I; Spannagl M; Sturm A; Singh D; Dechant C
    Transfus Med Hemother; 2019 Apr; 46(2):121-123. PubMed ID: 31191199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emicizumab for acquired haemophilia A: A case series.
    Engelen MM; Vandesande J; De Bent J; Van Laer C; Labarque V; Jacquemin M; Peerlinck K; Hermans C; Verhamme P; Vanassche T
    Haemophilia; 2023 Jul; 29(4):1049-1055. PubMed ID: 37276345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature.
    Thomas VM; Abou-Ismail MY; Lim MY
    Haemophilia; 2022 Jan; 28(1):4-17. PubMed ID: 34820989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report.
    Al-Banaa K; Alhillan A; Hawa F; Mahmood R; Zaki A; El Abdallah M; Zimmerman J; Musa F
    Am J Case Rep; 2019 Jul; 20():1046-1048. PubMed ID: 31318850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab: A Review in Haemophilia A.
    Blair HA
    Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emicizumab: Review of the literature and critical appraisal.
    Rodriguez-Merchan EC; Valentino LA
    Haemophilia; 2019 Jan; 25(1):11-20. PubMed ID: 30431213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emicizumab in acquired haemophilia A: about two clinical cases and literature review.
    Hansenne A; Hermans C
    Ther Adv Hematol; 2021; 12():20406207211038193. PubMed ID: 34471508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis.
    Gelbenegger G; Traby L; Rahimi N; Knöbl P
    Br J Clin Pharmacol; 2023 Feb; 89(2):908-913. PubMed ID: 36369653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
    Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
    Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A.
    Hart C; Klamroth R; Sachs UJ; Greil R; Knoebl P; Oldenburg J; Miesbach W; Pfrepper C; Trautmann-Grill K; Pekrul I; Holstein K; Eichler H; Weigt C; Schipp D; Werwitzke S; Tiede A
    J Thromb Haemost; 2024 Jun; ():. PubMed ID: 38936699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the safety of emicizumab in patients with hemophilia A.
    Langer AL; Etra A; Aledort L
    Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra
    Susen S; Gruel Y; Godier A; Harroche A; Chambost H; Lasne D; Rauch A; Roullet S; Fontana P; Goudemand J; de Maistre E; Chamouard V; Wibaut B; Albaladejo P; Négrier C
    Haemophilia; 2019 Sep; 25(5):731-737. PubMed ID: 31294904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A.
    Al-Banaa K; Gallastegui-Crestani N; von Drygalski A
    Eur J Case Rep Intern Med; 2021; 8(11):002984. PubMed ID: 34912741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child.
    Chehade H; Cachat F; Beck-Popovic M; Rotman S; Diezi L; Albisetti M; Alberio L; Young G; Rizzi M
    Pediatrics; 2020 Nov; 146(5):. PubMed ID: 33122347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.